Details for Patent: 8,012,976

Which drugs does patent 8,012,976 protect, and when does it expire?

Patent 8,012,976 protects TALZENNA and is included in one NDA.

This patent has fifty-three patent family members in thirty countries.

Summary for Patent: 8,012,976

Title:	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Abstract:	A compound having the structure set forth in Formula (I) and Formula (II): ##STR00001## wherein the substituents Y, Z, A, B, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
Inventor(s):	Wang; Bing (San Jose, CA), Chu; Daniel (Santa Clara, CA)
Assignee:	BioMarin Pharmaceutical Inc. (Novato, CA)
Application Number:	12/510,096
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,012,976

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-001	Oct 16, 2018		RX	Yes	No			Y	Y
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-003	Sep 20, 2021		RX	Yes	No			Y	Y
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-004	Sep 20, 2021		RX	Yes	No			Y	Y
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-002	Oct 16, 2018		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,012,976

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072970
Australia	2009279944
Brazil	PI0917119
Canada	2732797